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SUMMARY
Voltage-gated sodium channels are targets for many analgesic and antiepileptic drugs whose therapeutic
mechanisms and binding sites have been well characterized. We describe the identification of a previously
unidentified receptor site within the NavMs voltage-gated sodium channel. Tamoxifen, an estrogen receptor
modulator, and its primary and secondary metabolic products bind at the intracellular exit of the channel,
which is a site that is distinct from other previously characterized sodium channel drug sites. These com-
pounds inhibit NavMs and human sodium channels with similar potencies and prevent sodium conductance
by delaying channel recovery from the inactivated state. This study therefore not only describes the structure
and pharmacology of a site that could be leveraged for the development of new drugs for the treatment of
sodium channelopathies but may also have important implications for off-target health effects of this widely
used therapeutic drug.
INTRODUCTION
Voltage-gated sodium channels (Navs) form ion-conducting
pores responsible for electrical signaling in nerves and cardiac
cells. Variants in human voltage-gated sodium channel isoforms
(hNav1.1–1.9) are associated with a range of diseases, including
epilepsy, chronic pain, and cardiomyopathy. A number of
commonly used antiepileptic and analgesic drugs, such as lamo-
trigine and lidocaine, have been developed to inhibit or modulate
their ion-conducting properties. Prokaryotic Navs are homote-
tramers, with each subunit consisting of a four-helix voltage
sensor module (VSM) and a two-helix pore module (PM). Pro-
karyotic Navs are analogous to human Navs, except that the
latter are encoded by a single peptide composed of four do-
mains, each of which contains a VSM and a PM. The structures
of a number of prokaryotic and eukaryotic Navs have been eluci-
dated in recent years using X-ray crystallography and cryoelec-
tron microscopy (cryo-EM) methods (Payandeh et al., 2011;
Ulmschneider et al., 2013; Sula et al., 2017; Ahuja et al., 2015;
Xu et al., 2019; Pan et al., 2019; Shen et al., 2018; Bagnéris
et al., 2014). Those studies have demonstrated that prokaryotic
and eukaryotic sodium channels share a high degree of similarity
in overall fold and assembly, with the exception of their intra- and
extracellular loops and termini (Figure S1A). One prokaryotic
channel, NavMs fromMagnetococcus marinus, has been shown
to be a particularly good exemplar for hNav pharmacology in
terms of drug potency, mechanism of drug inhibition, and recep-
tor site interactions (Bagnéris et al., 2014).
Tamoxifen was developed as a treatment for breast cancer
more than 40 years ago and is currently prescribed to more
than 200 million patients worldwide (Errico, 2015; Jordan,
2003; https://clincalc.com/DrugStats/Top300Drugs.aspx). Apart
from its therapeutic effects targeting the estrogen receptor (ER)
(Shiau et al., 1998), electrophysiology studies have demon-
strated that tamoxifen antagonizes sodium currents from meta-
static adenocarcinoma and glioma cells (Fraser et al., 2005;
Wang and Jiao, 2009). To date, however, its sodium channel re-
ceptor site and mechanism of inhibition have not been defined.
Its therapeutic activity in cancer cells has been linked to antag-
onism of the ER, but its off-target effects, such as binding to
and inhibiting Navs expressed in excitable cells such as neu-
rons, might be responsible for side effects and limitations in clin-
ical safety (Fraser et al., 2014; Klein et al., 2013; M€urdter et al.,
2011; He et al., 2003).
Tamoxifen metabolism occurs mainly through two path-
ways, involving 4-hydroxylation and N-demethylation, result-
ing in the primary metabolites 4-hydroxytamoxifen and N-des-
methyltamoxifen, and the secondary metabolite endoxifen
(Helland et al., 2017; Kisanga et al., 2004; Lien et al., 1991a,
1991b) (Figure S2). For this reason, we have explored the
structural and functional effects not only of tamoxifen itself
but also those of its metabolic products. X-ray crystallo-
graphic studies of the complexes formed with these com-
pounds define two occupancy sites located near the intracel-
lular gate of the channel. Functional studies show that
tamoxifen antagonizes the NavMs channel activity through a
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unique mechanism, in which drug inhibition is dependent on
channel entry into the inactivated channel state. Similar po-
tencies for sodium current inhibition for all of these com-
pounds were observed in NavMs and human Nav channels.
RESULTS
An overview of the tamoxifen-bound NavMs structures
The crystal structures (Figures 1, 2, and 3; Table S1) of the
NavMs sodium channel complexes formed with tamoxifen
and its metabolites clearly show the positions of two unique
drug binding sites in the channel. The drugs are located
near the intracellular gate or exit of the transmembrane ion-
conducting pore (Figure 1). When compared with the apo-
NavMs open state structure, the C-terminal ends (starting at
I224) of the S6 helices in the drug-bound NavMs
channel structure are displaced toward the center of the
ion-conducting pathway (overall root-mean-square deviation
[RMSD] of 1.2 Å). This change in the channel conformation
creates a binding pocket between pore domains (Figures 2A
and 2B) and narrows the pore radius of the intracellular gate
from 2.3 Å (in the open channel) to 1.4 Å (Figure S3A). As
the S4 helices found in the VSMs are in the ‘‘up’’ position
and the PMs are in narrow, non-conductive conformations,
the new drug-bound structures may represent either the
‘‘pre-open’’ or ‘‘inactivated’’ states. In the channel-drug com-
plexes described in this study, eight tamoxifen (or tamoxifen
metabolite) molecules can bind per tetramer (Figure 1A), and
each tamoxifen molecule interacts with the S6 helices from
two different subunits. Notably, tamoxifen and its analogs
do not bind in the relatively wide and hydrophobic cavity
located in the middle of the transmembrane pore (Figure 2B),
where analgesic and antiepileptic drugs bind, nor do they
occupy the transmembrane fenestrations which have been
proposed (Hille, 1977) to provide the passageways for hydro-
phobic/uncharged drugs (Montini et al., 2018; Gamal El-Din
et al., 2018) to enter from the membrane lipid phase into the
central cavity of the transmembrane pore.
Figure 1. Overview of crystal structures of the NavMs sodium channel complexes with tamoxifen or its metabolic products
The top of each panel corresponds to the cell exterior, and the bottom corresponds to the cell interior. The approximate positions of the cell membrane surfaces
are denoted by the horizontal black lines. The three sodium ions present in the selectivity filter are shown as pink spheres. In all panels, the protein is depicted in
gold ribbonmotif, and the bound compounds are in stick representations (green, carbon; red, oxygen; blue, nitrogen). A total of eight copies of either tamoxifen or
a metabolite can bind into a single channel in two sets (designated ‘‘inner’’ and ‘‘outer’’) of four symmetry-related positions. The structures of the proteins in all of
these complexes are essentially identical, having overall RMSDs ranging from 0.21 to 0.5 Å.
(A) NavMs complex with 4-hydroxytamoxifen, indicating the locations of all eight copies (four ‘‘inner’’ and four ‘‘outer’’ sites) of the drug in the structure. This
illustrates the close packing of the compounds in the protein cavity that lies just above the intracellular exit of the channel.
(B) As in (A), except that this depicts (left) the wild-type NavMs complex with 4-hydroxytamoxifen and (right) the F208L mutant (NavMsL) complex with 4-hy-
droxytamoxifen. Both the wild-type and mutant proteins were examined for comparison, as this binding site residue is an F in two domains of the corresponding
humanNav1.2 protein and L in the two other domains of the human protein (Figure S6). For clarity, in these structures, only one copy of the drug is shown in each of
the two distinct ‘‘inner’’ and ‘‘outer’’ sites.
(C) NavMsL showing (for clarity) only one copy of tamoxifen bound in the ‘‘outer’’ site.
(D) As in (C), except that this depicts the NavMsL complexes with the other metabolites: (left) N-desmethyltamoxifen in the ‘‘inner’’ site and (right) NavMsL with
endoxifen in the ‘‘inner’’ site.
See also Figures S1 and S6 and Table S1.
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Tamoxifen analogs occupy inner andouter sites near the
channel gate
The structures of the NavMs channels in the complexes
formed in the presence of the three tamoxifen metabolic prod-
ucts (4-hydroxytamoxifen, N-desmethyltamoxifen, and endox-
ifen) (Figures 1B–1D) are very similar to one another (protein
Ca RMSDs of 0.35 Å) and to the complex with the parent
tamoxifen molecules (RMSDs of 0.5 Å). All of these com-
plexes exhibit two sets of four symmetry-related binding sites,
making a total of eight sites per channel (Figures 1A and S4).
The ‘‘outer’’ set of sites for 4-hydroxytamoxifen is closer to the
intracellular C-terminal portion of the channel and does not
involve any hydrogen bond interactions between the drugs
and the polypeptides (Figures 3C and 3D). The positions of
the drug molecules vary slightly among the different tamoxifen
metabolite structures (Figure S4), which along with their higher
crystallographic temperature (B) factors (Table S1) suggests
that drug coordination in this site is somewhat flexible. By
comparison, the 4-hydroxytamoxifen ‘‘inner’’ sites (Figures 1,
3A, 3B, and S4A–S4C) are better defined (lower average tem-
perature factors for the drug molecules; Table S1) and are
closer to the ion-conducting pathway. Binding to the ‘‘outer’’
site does not significantly change the pore radius (Figure S3),
indicating that drug binding would not interfere with sodium
ion egress from the channel. In contrast, the ‘‘inner’’ binding
sites for 4-hydroxytamoxifen (Figure 3B) and the other metab-
olites specifically involve residues M222 (the intracellular gate
residue), K226, E227, and I241 of one monomer and residues
D220, L245, and L246 of the other monomer. Drug binding at
these sites narrows the pore diameter at the cell interior end of
the channel (Figures S3A and S3B); comparisons of tamoxifen
docked into the corresponding site in hNav1.2 (Figures S3C
and S3D) show a similar narrowing. The drug hydroxyl groups
form hydrogen bonds with the E227 side chain of one poly-
peptide, and the drug amide groups form hydrogen bonds
with D220 side chain of a different polypeptide chain (Figures
3 and S4).
Potency of Nav inhibition and validation of the inner
tamoxifen receptor site
The whole-cell patch-clamp method was used to determine
the efficacy and potency of sodium current inhibition by
tamoxifen and its metabolic products in cells expressing
either NavMs or hNav1.2 channels (Figures 4A and 4B; Table
1). Among the metabolites tested, 4-hydroxytamoxifen was
the most potent for both NavMs and hNav1.2. Both Z and E
isomers of 4-hydroxytamoxifen inhibited the currents, but
the Z form was the more potent (half maximal inhibitory con-
centrations [IC50] of 239 nM for NavMs and 1.2 mM for
Nav1.2), indicating a possible stereoselectivity of the receptor
in Nav1.2 and NavMs channels (Table 1). As the drug interac-
tions with the channel were best resolved within the inner
binding site, where they appeared to involve H-bond forma-
tion with two of the protein side chains (D220 and E227), these
residues were individually mutated to alanines, but no voltage-
dependent Na+ currents (INa) could be measured from such
channels. However, when the residues at these sites were re-
placed with the alternative acidic residue (D swapped for E,
and vice versa), the channels retained functionality, but the
potency of 4-hydroxytamoxifen INa inhibition (IC50) was 7
times less than observed for the wild-type channel (Figure 3E;
Table 1). The changes in apparent affinity of 4-hydroxytamox-
ifen for these D220E and E227D channels correspond to
losses in the free energies of binding (DG) of 1.5 and
Figure 2. Comparisons of NavMs structures
in the absence and presence of tamoxifen
and its metabolites
(A) Overlaid ribbon representations of the poly-
peptide backbones of single monomers of
apo-NavMsL (gray), tamoxifen-NavMsL (green),
4-hydroxytamoxifen-NavMsL (red), N-desme-
thyltamoxifen-NavMsL (coral), and endoxifen-
NavMsL (blue), showing the main differences in the
polypeptide chains that occur upon binding any of
the compounds. Although the overall conforma-
tions of the apo and bound structures are essen-
tially identical throughout their transmembrane
domains (with an overall C-alpha RMSD of 1.35 Å),
in all of the complexed structures, the C-terminal
tails differ considerable from the apo structure,
starting at the C-terminal end of the S6 helix
(bottom of figure) (residue I224) (denoted by the
black circle) reaching an RMSD of 5.9 Å at residue
P240, the last residue before the intracellular coil-
coiled region (denoted by the dashed orange box), which is clearly displaced from the location of this region in the apo structure. All of the rest of the
polypeptide chain structures are essentially identical for all of the complexes (maximum deviations of 0.2–0.5 Å).
(B) Electrostatic surface representations of (left) the apo-NavMs crystal structure, and (right) the 4-hydroxytamoxifen-NavMs complex. The drug (depicted in
green stick representation) is just visible in the opening above the C-terminal intracellular domain denoted within the orange box. The lower right panel shows
a vertical slice through the middle of the 4-hydroxytamoxifen complex, where the compound (in green stick representation) is clearly visible (in the purple box)
at the bottom of the transmembrane channel pore. This is a region distinct from, and below, the central hydrophobic cavity (denoted by the black box) which
is considered to be the binding sites for many analgesic and anesthetic compounds.
See also Figure S3.
ll
OPEN ACCESSArticle
Molecular Cell 81, 1–10, March 18, 2021 3
Please cite this article in press as: Sula et al., A tamoxifen receptor within a voltage-gated sodium channel, Molecular Cell (2021), https://doi.org/
10.1016/j.molcel.2020.12.048
1.4 kcal/mol, respectively (Figure 3F). The structural and func-
tional findings therefore suggest that these substitutions
disrupt the optimal hydrogen bond coordination distance
made between the side chain carboxylates and the amine
and hydroxyl moieties of 4-hydroxytamoxifen (Figure 3B). It
is notable that NavMs and hNav1.2 share similar folds (Fig-
ure S1A) and that these NavMs tamoxifen receptor residues
are conserved in domains III and IV of hNav1.2 (Figure S1E).
Tamoxifen and its primary metabolic products bind in
similar sites
Tamoxifen metabolism occurs mainly through two pathways,
4-hydroxylation and N-demethylation, resulting in the very
potent secondary metabolite, endoxifen (Figure S2) (Helland
et al., 2017; Kisanga et al., 2004; Lien et al., 1991a, 1991b).
The primary metabolite, 4-hydroxytamoxifen, was originally
shown to be 30- to 100-fold more potent in vivo as an anti-
estrogen than tamoxifen itself. However, the pathway that pro-
duces it only contributes minimally to tamoxifen metabolism.
The conversion of tamoxifen by N-demethylation to N-desme-
thyltamoxifen is catalyzed primarily by CYP3A4 and CYP3A5
liver enzymes and contributes to 92% of tamoxifen meta-
bolism. However, N-desmethyltamoxifen binds to ER with an
affinity 100 times lower than that of tamoxifen itself. The
secondary metabolite endoxifen, which contains both the
4-hydroxylation and N-desmethylation modifications, is the
primary binder to ERs in vivo (Helland et al., 2017; Kisanga
et al., 2004; Lien et al., 1991a, 1991b). For these reasons the
binding sites of not only tamoxifen itself but that of its primary
metabolic products, 4-hydroxytamoxifen and N-desmethylta-
moxifen, and its secondary metabolite, endoxifen, were stud-
ied. All of these compounds formed crystal complexes with
NavMs (Figure 1; Table S1), and the ‘‘inner’’ and ‘‘outer’’
drug binding sites were located in the same regions of the
molecule, near the bottom of the transmembrane region (Fig-
ure 2). These pockets are also present in the structure of
hNav1.2 (Figures S1C and S1D), but instead of being formed
from the four polypeptide chains in NavMs, they are formed
from different regions of the four human channel domains.
Comparing tamoxifen sites within NavMs and the ER
The widely accepted molecular target of tamoxifen and its deriv-
atives is the intracellular ER (Shiau et al., 1998), where the ER-ta-
moxifen complex binds to DNA and regulates gene transcription.
Most interestingly, the three-dimensional binding sites of the
4-hydroxytamoxifen metabolite in the on-target (ER) and off-
target (sodium channel) proteins show similar features (Fig-
ure 5A). Although there is effectively no sequence or overall
structural or even fold similarity between NavMs and the ER
(Shiau et al., 1998), comparisons of the crystal structures of their
Figure 3. Detailed views of the ‘‘inner’’ and
‘‘outer’’ binding sites in the 4-hydroxytamox-
ifen NavMs complex
There are no steric clashes between any of the sites,
so all eight positions can be occupied simulta-
neously. For clarity, in this figure only one of the four
equivalent positions of each type of site is shown.
(A) The ‘‘inner’’ binding site. Left: the crystal struc-
ture of NavMs (in ribbon depiction for the four
polypeptide chains, which are colored differently),
with the 4-hydroxytamoxifen molecule shown in
stick depiction overlaying (in blue mesh) the (2Fo –
Fc, contoured at 1.5 sigma) electron density map.
Right: detailed view of the binding site and its
location between two different polypeptide chains
(colored in blue and coral).
(B) More detailed view of the ‘‘inner’’ binding site,
showing the (2Fo – Fc, contoured at 1.5 sigma)
electron density map (blue mesh) of the 4-hydrox-
ytamoxifen overlaying the protein structure, with the
adjacent protein side chains in stick depiction
(colored by chain, with residue numbers labeled).
The right and left panels depict twoviews of the same
site, rotated to show a clear view of the molecule.
(C and D) As in (A) and (B), except depicting the
‘‘outer’’ sites with their (2Fo – Fc, contoured at 1
sigma) electron density maps.
(E) 4-Hydroxytamoxifen dose-response curves
generated for the NavMs, D220E and E227Dmutant
channels, which disrupt the ‘‘inner’’ binding. n = 4
cells tested at each concentration, and error bars
are equal to SD.
(F) Change in free energy of 4-hydroxytamoxifen
binding to D220E and E227Dmutants relative to WT
NavMs channels.
See also Figure S4.
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binding sites reveal that specific geometric details of the resi-
dues involved in the binding sites in both are similar, including
hydrogen bonds with an aspartic acid (D351 in ER and D220 in
NavMs) at one end and a glutamate (E353 in ER and E227 in
NavMs) at the other, which correspond with the critical residues
identified structurally and functionally, as described above. Both
the NavMs and ER pockets are of sufficient size to accommo-
date the large and hydrophobic 4-hydroxytamoxifen molecules.
This strong local similarity would thus potentially enable tamox-
ifen and its derivatives to bind to and inhibit both the target ER
and the unrelated Navs and could be the origin of its adventitious
off-target effects in Navs previously reported in adenocarcinoma
cells. To test this, voltage clamping of MDA-MB-231 cells (a tri-
ple-negative breast cancer cell line that functionally expresses
Nav1.7 and the neonatal splice form of Nav1.5 [nNav1.5] but
does not express the ER [Gradek et al., 2019; Brackenbury
et al., 2007]) produced endogenous sodium currents which
exhibit low sensitivity to tetrodotoxin (TTX) (IC50 = 2.6 mM), sug-
gesting that the preponderance of the current is conducted by
Figure 4. Functional studies showing sodium
current inhibition by tamoxifen analogs
(A and B) HEK293 cells transfected with either (A)
NavMs or (B) hNav1.2 were voltage-clamped in the
whole-cell configuration. Exemplar voltage-gated
sodium currents (INa) recorded in control conditions
and in the presence of increasing concentrations of
extracellular tamoxifen derivatives. Currents were
activated by a 0.5 Hz train of depolarizations to the
indicated potentials (gray), and INa inhibition was
evaluated after 2 min in each condition. Right
panels: the resulting drug concentration-percent-
age sodium current inhibition (% INa inhibition) re-
lationships were fit to the Hill equation to estimate
the half maximal inhibitory concentration (IC50). Er-
ror bars are equal to 1 SD, and four to seven cells
were tested for each concentration of the drug.
TTX-insensitive Nav subtypes (Figures 5B
and 5C). 4-Hydroxytamoxifen produces
dose-dependent inhibition of the INa with
an IC50 of 890 nM (Figure 5C; Table 1),
which demonstrates that the efficacy and
potency of this drug against endogenous
nNav1.5 in these cancer cells is indepen-
dent of ER modulation. This study thus
provides a structural basis for the observa-
tions of its effects on sodium transport in
these adenocarcinoma cells.
The mechanism of sodium current
inhibition by 4-hydroxytamoxifen
Therapeutic drugs inhibit sodium chan-
nels by either blocking the ion-conducting
pathway or stabilizing the non-conducting
(closed or inactivated) conformations of
the channel (Sampson and Kass, 2011;
McNamara, 2011; Catterall and Mackie,
2011). The kinetics of 4-hydroxytamoxifen
INa inhibition (ton) and recovery (toff) were 16 and 765 times
slower, respectively, than those observed for the pore-blocking
metal ion cadmium (Figures 6A and 6B). The delay in INa recov-
ery (toff = 6.6 min) is consistent with high-affinity drug occu-
pancy of the channel. To examine the mechanism of INa inhibi-
tion, the voltage dependence of activation and inactivation
were compared before and after 3 mM 4-hydroxytamoxifen
treatment, but no significant shifts in either parameter (Fig-
ure S5A) were observed. However, the rate of recovery from
inactivation (trec) did show a 10-fold delay following drug
treatment (Figure S5B). This suggests that the primary mecha-
nism of INa inhibition by 4-hydroxytamoxifen is a stabilization of
the non-conducting inactivated channel state. To further
explore the mechanism of drug action, we tested INa inhibition
from cells subjected to long (150 ms) depolarization trains,
where 95% of total current is inactivated by the end of the
voltage step (Figure 6C). NavMs channels recover from inacti-
vation in the control condition, as the magnitude of INa stayed
the same for each depolarization. Then, the depolarization train
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was terminated, and the channels were held in the closed state
(180 mV holding potential) while the cell was exposed to 1 mM
4-hydroxytamoxifen. Cells were then returned to the control
condition and the depolarization train was re-initiated. INa was
unchanged in the first depolarization, but surprisingly, clear in-
hibition was observed in subsequent depolarizations even
though the cell was no longer in the presence of 4-hydroxyta-
moxifen. Repeating these experiments, but limiting the percent-
age of channels entering the inactivated state (5%) using a
shorter depolarization time (7 ms) resulted in 3.4 times less
INa inhibition, which clearly demonstrates that the drug effect
is dependent on channel entry into the inactivated state (Fig-
ures 6D–6F). These results provide clear evidence that tamox-
ifen binds to sodium channels with high affinity and inhibits the
sodium current using a unique mechanism and establish a
functional link with the structural studies.
DISCUSSION
In summary, this study has demonstrated that tamoxifen and its
metabolic products bind to the prokaryotic sodium channel
NavMs through a binding pocket that is structurally conserved
in eukaryotic Nav homologs. The tamoxifen-NavMs receptor
site is entirely different from both the hydrophobic transmem-
brane cavity used by analgesic and antiepileptic drugs as bind-
ing sites and the voltage sensor receptor sites used by toxins
and other hydrophilic inhibitors. Furthermore, the electrophysi-
ology studies have shown that the NavMs-tamoxifen interaction
is high affinity and demarked by slow dissociation, which delays
the channel recovery from inactivation. These pharmacological
features are shared by neuronal sodium channels and endoge-
nous sodium channel currents in metastatic breast cancer cells.
The measured binding affinities are consistent with the structural
observation that the residues that form the binding pockets for
tamoxifen in sodium channels are geometrically similar to those
in the target ERs. These results define a new sodium channel
drug receptor site, which could be targeted in future drug devel-
opment studies, as well as highlighting a new mechanism of
channel inhibition involving inactivation, which could also be ex-
ploited for the future development of novel on-target drugs to
treat sodium channelopathies. The observed effects on sodium
channel structure and function also have potentially important
ramifications for the therapeutic use and consequent side effects
of tamoxifen in cancer treatments.
Limitations
This study has demonstrated potential interactions of Navs to
bind and be modulated by tamoxifen and its principal meta-
bolic products in vitro at concentrations that approximate
ranges commensurate with dosages used for in vivo prophy-
laxis and chemotherapeutic treatments. However, as with all
such studies, the translation of molecular characterizations
to in vivo applications is potentially less straightforward.
Nevertheless, the newly characterized interactions described
in this study may open up a future avenue for development
of other pharmaceuticals for Nav targets.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Tamoxifen 830 ± 85 nM
(1.08 ± 0.1)
NT NT 2.4 ± 0.11 mM
(1.05 ± 0.1)
NT
Endoxifen 328 ± 89 nM
(1.09 ± 0.1)
NT NT 3.1 ± 0.13 mM
(0.97 ± 0.1)
NT
4OH-Tam 297 ± 75 nM
(1.14 ± 0.1)
3.6 ± 0.14 mM
(1.17 ± 0.1)
2.8 ± 0.16 mM
(1.13 ± 0.1)
2.1 ± 0.14 mM
(0.96 ± 0.1)
889 ± 98 nM
(0.98 ± 0.1)
NM-Tam 1.1 ± 0.16 mM
(1.11 ± 0.1)
NT NT 3.2 ± 0.12 mM
(0.96 ± 0.1)
NT
E-4OH-Tam 2.3 ± 0.18 mM
(1.15 ± 0.1)
NT NT 4.2 ± 0.15 mM
(0.94 ± 0.1)
NT
Z-4OH-Tam 239 ± 87 nM
(1.05 ± 0.1)
NT NT 1.2 ± 0.12 mM
(0.95 ± 0.1)
NT
TTX NT NT NT NT 2.6 ± 0.17 mM
(1.01 ± 0.1)
Listed are the average IC50 values derived from fitting the dose-response data to the Hill equation. The average slopes of the fits are indicated in pa-
rentheses. The drugs tested in the study were tamoxifen, endoxifen,N-desmethyltamoxifen (NM-Tam), 4-hydroxytamoxifen (4OH-Tam), and the E and
Z isomers of 4OH-Tam. NT indicates conditions not tested. Error is equal to SD.
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Figure 5. Tamoxifen binding in the estrogen
receptor and the NavMs channel and its inhi-
bition of sodium currents recorded from
adenocarcinoma cells
(A) Stereo image of overlays of the 4-hydrox-
ytamoxifen binding sites in NavMs (PDB: 6SXC) (dark
green) and in the estrogen receptor (dark pink) (PDB:
3ERT). This shows the similarities of the binding site
geometries and residues that form hydrogen bonds
(Asp at one end and Glu at other end) involved in the
interactions of the compound (shown in corre-
sponding light green and light pink stick depictions)
with both target proteins. The side chains of the
NavMs and estrogen receptor protein molecules are
depicted in dark green and dark pink, respectively.
(B) Endogenous sodium currents recorded from the
adenocarcinoma cell line MDA-MB-231 cells. Left:
exemplar voltage-gated sodium currents activated
by successively increasing the depolarizing potential
by 5 mV from a 100 mV holding potential before
and after TTX treatment. Right: resulting current
densities plotted as a function of voltage.
(C) Left: exemplar INa recorded from MDA-MB-231
cells and their inhibition by 4-hydroxytamoxifen us-
ing the same protocol described in Figure 4. Right,
drug concentration-percentage sodium current in-
hibition relationships for TTX and 4-hydroxytamox-
ifen as described in Figure 4. Error bars denote
SD, and number of cells tested is indicated in
parentheses.
See also Figure S2.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial strains
Escherichia coli NEB 5-alpha New England Biolabs Cat# C2987H
Escherichia coli OverExpress C41 (DE3) Sigma-Aldrich Cat# CMC0017
Chemicals, peptides, and recombinant proteins
Tamoxifen Sigma-Aldrich Cat# T5648
Tamoxifen Citrate Sigma-Aldrich Cat# T9262
4-Hydroxytamoxifen hydrochloride Sigma-Aldrich Cat# H6278
Endoxifen hydrochloride Sigma-Aldrich Cat# E8284
N-Desmethyltamoxifen hydrochloride Sigma-Aldrich Cat# D9069
Z-4-Hydroxytamoxifen hydrochloride Abcam Cat# ab141943
E-4-Hydroxytamoxifen hydrochloride Abcam Cat# ab143637
Z-Endoxifen hydrochloride Generon Cat# HY-18719A
E-Endoxifen hydrochloride Generon Cat# HY-18719C
Polyethylene Glycol 400 Sigma-Aldrich Cat# 202398
Ethylene Glycol Molecular Dimensions Cat# MD2-100-158
Dimethyl Sulphoxide (DMSO) Sigma-Aldrich Cat# D4540
n-Dodecyl-B-D-maltoside (DDM) Anatrace Cat# D310S
Decanoyl-N-Hydroxyethylglucamide (HEGA-10) Anatrace Cat# H110
Cesium Fluoride Sigma-Aldrich Cat# 198323
Cesium Hydroxide Fisher Chemical Cat# C97
Calcium Chloride dihydrate Sigma-Aldrich Cat# C3306
Ethylene glycol-bis(2-amino ethylether)- N,N,N’,N’-
tetraacetic acid (EGTA)
Sigma-Aldrich Cat# E4378
HEPES Fisher Chemical Cat# BP310
D-Mannitol Acros Organics Cat# 69658
Deposited data
Crystal structure of NavMs Sula et al., 2017 PDB: 5HVX
CryoEM Structure hNav1.2 Pan et al., 2019 PDB: 6J8E
NavMS F208L (NavMsL) This Study PDB: 6SX5
NavMs/4-Hydroxytamoxifen This Study PDB: 6SXG
NavMsL/Tamoxifen This Study PDB: 6SXF
NavMsL/4-Hydroxytamoxifen This Study PDB: 6SXC
NavMsL/Endoxifen This Study PDB: 6SXE
NavMsL/N-Desmethytamoxifen This Study PDB: 6Z8C
NavMsL/DMSO This Study PDB: 6SX7
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pET15b-NavMS Sula et al., 2017 N/A
pET15b-NavMS F208L This Study N/A
pTracer-CMV2-NavMS Sula et al., 2017 Addgene #100004
pTracer-CMV2-NavMS D220E E227D This Study N/A
Human Nav1.2/Pcdna8 This Study N/A
Software and algorithms
XDS Kabsch., 2010 http://xds.mpimf-heidelberg.mpg.
de/html_doc/XDS.html
Collaborative Computational Project No.4 Winn et al., 2011 https://www.ccp4.ac.uk/
Aimless Evans and Murshudov, 2013 https://www.ccp4.ac.uk/dist/html/
aimless.html
Phaser McCoy et al., 2007 https://www.ccp4.ac.uk/html/
phaser.html
Coot Emsley et al., 2010 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
Refmac Murshudov et al., 2011 https://www.ccp4.ac.uk/html/
refmac5.html
Buster version 1.10.0 Bricogne et al., 2011 https://www.globalphasing.com/
buster/
MolProbity Chen et al., 2010 molprobity.biochem.duke.edu
CCP4mg McNicholas et al., 2011 https://www.ccp4.ac.uk/MG/
Clustal Omega Sievers et al., 2011 https://www.ebi.ac.uk/Tools/
msa/clustalo/
HOLE Smart et al., 1996 http://www.holeprogram.org/
VMD Humphrey et al., 1996 https://www.ks.uiuc.edu/
Research/vmd/




Igor Pro 7.00 Wavemetrics Inc https://www.wavemetrics.com/
products/igorpro
Other
His Trap FF GE Healthcare Cat# 17-5255-01
Superdex 10/300 200 GL Increase GE Healthcare Cat# 28990944
Amicon Ultra-15 Centrifuge 100K Merck Cat# UFC910024
Amicon Ultra-6 Centrifuge 100K Merck Cat# UFC810024
MemMeso Crystallization Screen Molecular Dimensions Cat# MD1-86
MRC 2 Well Crystallization Plate Molecular Dimensions Cat# MD11-00-10
Borosilicate Glass Capillaries World Precision Instruments, Inc. Cat# IB150F-4
Patch-Clamp Amplifier Axon Instruments Axopatch 200B
Data Acquisition Digitizer Axon Instruments Axon Digidata 1550B
Perfusion Fast-step Warner Instrument Corporation SF-77B
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, B.A.
Wallace (b.wallace@cryst.bbk.ac.uk).
Materials availability
Reagents generated in this study will be made available on request, but may require a completed Materials Transfer Agreement and/
or payment, if there is potential for commercial application. The pTracer-CMV2, IRESGFP plasmidwhich contains the gene encoding
for N-terminal his-tagged NavMs is available through addgene (http://www.addgene.org/100004), whereas the pcdna8 plasmid con-
taining the human gene encoding for the Nav1.2 is also available upon request.
Data and code availability
The accession numbers for the crystal structure coordinates and structure factors deposited in the Protein Data Bank are: PDB:
6SX5, 6SXF, 6SXG, 6SXC, 6SXE, 6Z8C, and 6SX7.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Microbe strains
E. coli DH5 alpha was cultured at 37C in LB medium supplemented with 100 mg/ml of ampicillin for plasmid DNA extraction. E. coli
C41 (DE3) was cultured at 37C in LB medium supplemented with 100 mg/ml of ampicillin for protein overexpression.
Cell lines
HEK293 (Human Embryonic Kidney) andMDA-MD-231 cells were propagated andmaintained in Dulbecco’sModified EagleMedium
(DMEM)/F12 + GlutaMAX supplemented with 10% fetal bovine serum and 1% penicillin streptomycin solution.
METHOD DETAILS
Protein expression and purification
NavMs proteins were expressed and purified as previously described (Sula et al., 2017). The F208L (NavMsL) mutation (Figure S6)
was introduced using the SLIM site-directed mutagenesis protocol (Chiu et al., 2004). The sequence was verified by Source Biosci-
ence, UK.
Crystallization
Proteins were concentrated to 10 mg/ml for crystallizations in 20 mM Tris-HCl, 300 mM NaCl, 14 mM HEGA-10 detergent, pH 7.5,
and stored at 80C. Crystals were grown at 4C using the sitting drop vapor diffusion method by mixing 2:1 ratios of protein and
reservoir solution, which typically contained 30% v/v PEG400, 0.1 M NaCl, 0.1 M MES, pH 6.5. Crystal conditions were refined for
each crystal type using the four-corner screen method. Details of the precise conditions for individual crystals are documented in the
PDB files for their structures. For co-crystallizations, prior to setting up the drops, 50 mM stocks of tamoxifen, 4-hydroxytamoxifen,
N-desmethyltamoxifen, or endoxifen (Sigma-Aldrich) were prepared in 100% DMSO and added to the protein solutions to produce
final concentrations of 1.25mMdrug and 2.5%v/v DMSO. DMSO-only controls were also set up in the sameway and yielded crystals
identical to the apo-NavMs and apo-NavMsL crystals grown in the absence of any additives. Crystals were flash-frozen prior to data
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Inverted Microscope Olympus IX73
Thrombin Sigma-Aldrich Cat# 69671
Trypsin Thermo Fisher Scientific Cat# R001100
DMEM/F12 + GlutaMAX Thermo Fisher Scientific Cat# 10565018
Penicillin-Streptomycin Thermo Fisher Scientific Cat# 15140122
USA Origin Fetal Bovine Serum (FBS) Sigma-Aldrich Cat# F2442
Lipofectamine 2000 Thermo Fisher Scientific Cat# 11668027
Complete EDTA free Protease inhibitor tables Sigma-Aldrich Cat# 5056489001
KAPA HiFi Hotstart ReadyMix (2x) Roche Cat# KK2601
Collagenase Thermo Fisher Scientific Cat# 17018029
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collection. All crystallization conditions contained low molecular weight PEG which acted as the cryoprotectant. Both wild-type and
NavMsL proteins were examined because while the native residue at the site of themutation is phenylalanine in NavMs and the equiv-
alent residues in two of the domains of all hNavs are also phenylalanines, in the other two domains of hNavs the residue type is a
leucine (Figures S1 and S6). Comparisons of the apo-NavMs and apo-NavMsL proteins (PDB: 6SX5, 5HVX) and 4-hydroxytamoxi-
fen-bound structures (PDB 6SXC, 6SXG) (Figure S6; Table S1) demonstrated no effect on the apo-protein structure (Figure S6)
nor on the drug interactions (Figure S6). However, the NavMsL crystals were generally of slightly higher quality (better resolution),
and for that reason the other structures of crystal-drug complexes reported in this study are for NavMsL.
Crystallography
X-ray diffraction data were collected at either the EMBL Hamburg synchrotron (Germany) P13 beamline or at the I04, I03, or I24
beamlines at the Diamond (UK) synchrotron. More than 100 datasets were collected from the various crystal types. The highest res-
olution crystals of the native and NavMsL proteins and of the protein/drug complexes were 2.2 Å. Because there was a substantial
variation in the unit cell dimensions and resolution between different crystals produced under the same conditions, as we have seen
previously (Naylor et al., 2016) we were unable to merge datasets between crystals. The diffraction images were integrated and
scaled using the XDS software package (Kabsch, 2010) and merged using Aimless (Evans and Murshudov, 2013) in the CCP4 pro-
gram suite (Winn et al., 2011). The structures were determined bymolecular replacement using the full-length NavMs structure (PDB:
5HVX) as the searchmodel. Phases were obtained with Phaser (McCoy et al., 2007) andmodel building was performed in Coot (Ems-
ley et al., 2010). The structures were initially refined in Refmac (Murshudov et al., 2011) and then the refinement was continued in
Buster (Bricogne et al., 2011). The data collection, processing and refinement statistics are listed in Table S1. The refinement quality
was checked using MolProbity (Chen et al., 2010) which indicated that 100% of residues were in allowed conformations. Figures
were created in CCP4mg (McNicholas et al., 2011) unless otherwise noted.
Bioinformatics
Sequence alignments (Figure S1) were undertaken using the Clustal Omega multiple sequence alignment tool (Sievers et al., 2011),
with Uniprot codes A0L5S6 (NavMs) and Q99250 (hNav 1.2). The inner pore dimensions were calculated using the HOLE suite of pro-
grammes (Smart et al., 1996) and visualized with the Visual Molecular Dynamics (VMD) program (Humphrey et al., 1996), Molecular
overlays/comparisons of the NavMs/4-hydroxytamoxifen crystal structure (PDB: 6SXG) and hNav1.2 cryo-EM structure (PDB: 6J8E)
were accomplished using CCP4mg software (McNicholas et al., 2011). Structural overlays of 4-hydoxytamoxifen complexes of
NavMsL (PDB: 6SXC) and the human estrogen receptor (PDB: 3ERT) were done using CCP4mg (McNicholas et al., 2011) software
to maximize the overlay of the tamoxifen molecules in each structure.
Electrophysiology
The MDA-MB-231 and HEK cell lines were obtained from the American Type Culture Collection. The previously described pTracer-
CMV2, IRES GFP plasmid which contains the gene encoding for N-terminal his-tagged NavMs used for our whole-cell electrophys-
iology studies. Standard quick-change site directedmutagenesis protocols were used to create receptor site mutations in the NavMs
gene. Transient transfection of exogenous sodium channels (NavMs or hNav1.2) was performed using lipofectamine 24-48 hours
prior to electrophysiology recordings. Plasma membrane currents were recorded using borosilicate glass electrodes polished to re-
sistances of 2–4.5MU filled with an internal solution containing 110mMCsF, 30mMNaCl, 10mMHEPES, and 5mMEGTA (ethylene
glycol-bisb-aminoethyl ether-N,N,N0,N0-tetraacetic acid); the pH was adjusted to 7.3 using CsOH. The extracellular recording solu-
tion contained 150 mM NaCl, 10 mM HEPES, and 1.8 mM CaCl2, with the pH adjusted to 7.4 using NaOH. All solutions were osmot-
ically balanced to 300 (±10) mOsm with mannitol. Data were collected using an Axopatch 200B patch-clamp amplifier, Digidata
1550B, and pClamp 10 software. Currents were digitized at 25 kHz and low-pass filtered at 5 kHz. Tamoxifen, 4-hydroxytamoxifen,
endoxifen and N-desmethyltamoxifen were purchased from Sigma Aldrich. The 4-hydroxytamoxifen stocks contained at least 70%
of the Z- isomer according tomanufacturer documentation. The purified E- and Z- isomers of 4-hydroxytamoxifen (Abcam) were also
tested. All drug reagents were formulated in DMSO at 10mMand stored at20C. Rapid extracellular drug application was achieved
using a Warner Perfusion Fast-Step system in which the patched cells were held in the perfusate stream.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analyses of electrophysiological data
Data were analyzed by Igor Pro 7.00 (Wavemetrics, Lake Oswego, OR). Conductance (G)-voltage relationships were derived from the
peak sodium current measured during the prepulse of Figure S5 using the following equation: G = I/(V-Vr), where Vr is equal to the
reversal potential. Half-activation and inactivation voltages (V1/2) were derived by fitting the datasets by using a Boltzmann function:
f(x) = 1/[1+exp(VV1/2)/k]. Percent inhibition was determined by taking the ratio of the current at steady state drug block (Idrug) and the
control current (Icontrol), and expressed as: %INa inhibition = 100 - (Idrug/Icontrol)*100. Drug concentration-response curves were fit to
the Hill equation: f(x) = base+(max-base)/{1+(IC50/[Drug]} to estimate the concentration of drug (IC50) required to half-maximally
inhibit the sodium current. Gibbs law of free energy was used to calculate the free energy of drug binding: DG = -R$T$Ln(Kd), where
R = 0.008314 kJ/mol, temperature T = 297 K, and Kd is the apparent association constant estimated by the IC50. After an inactivating
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prepulse, the recovery from inactivation (trec) was estimated by fitting the normalized current activated by the test pulse to an expo-
nential equation: f(x) = base+amplitude$exp[(1/t)x]. This equation was also used to estimate the rate of channel inhibition (ton) and
recovery from inhibition (toff) by cadmium and 4-hydroxytamoxifen.
Estimations
Protein concentrations were estimated from Nanodrop absorbances measured at 280 nm, using an extinction coefficient of
29450 M-1 cm-1.
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